Archive · 19 Jun 2025
FDA Approves Twice-Yearly HIV Prevention Injection Yeztugo
A new shot called Yeztugo has been approved to help prevent HIV.
It only needs to be given twice a year.
This shot is very effective.
It's for people who want a way to protect themselves without taking daily pills.
The shot has some side effects like reactions at the injection site, headache, and nausea.
The main concern is the cost, which may make it hard for some people to get.
FDA approved lenacapavir (Yeztugo), a bi-annual HIV prevention injection.
The drug showed over 99.9% effectiveness in preventing HIV in clinical trials.
Yeztugo is for adults and adolescents at high risk of HIV.
Reported side effects include injection site reactions, headache, and nausea.
High cost raises concerns about accessibility.
- Who
- Gilead Sciences and adults and adolescents at high risk of HIV.
- What
- FDA approved the twice-yearly HIV prevention injection, lenacapavir (Yeztugo).
- When
- Recently.
- Where
- United States and potentially globally.
- Why
- To provide a more convenient and effective preventative option for HIV.
Cost and Accessibility Concerns
Benefits of the New Drug
Drug Affordability
Cost and Accessibility Concerns
The high cost of Yeztugo may limit access for many.
Benefits of the New Drug
Gilead aims to make the drug globally accessible.
- Drug Name
- lenacapavir (Yeztugo)
- Administration
- Two injections per year
- Purpose
- HIV Prevention
- Effectiveness
- Over 99.9% effective in trials
- Manufacturer
- Gilead Sciences
- Side Effects
- Injection site reactions, headache, nausea
Sources
FDA Approves World's Only Twice-a-year Shot to Prevent HIV
Breakthrough: US FDA approves twice-yearly injection for HIV prevention
Gilead's bi-annual HIV prevention jab gets FDA approval: How much does it cost and how it works? All you need to know…